AFMD News and Press, Affimed N.V. From 09/12/23

AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the treatment in patients with relapsed/refractory Hodgkin lymphoma The FDA’s fast track de...

HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the H.C. Wainwrigh...

2023-08-23 06:00:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Although relative few investors – let alone analysts hired by top research institutions – give much thought to low-volume speculative securities, the concept of top Wall Street ...

By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation pH Leveraging the full potential of FcRn-pH-HPLC enables Affimed an early selection o...

2023-08-10 11:57:08 ET Affimed N.V. (AFMD) Q2 2023 Earnings Call Transcript August 10, 2023 08:30 AM ET Company Participants Alex Fudukidis - Director of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Medical Officer Angus Sm...

2023-08-10 06:57:00 ET Affimed press release ( NASDAQ: AFMD ): Q2 GAAP EPS of -€0.20. Revenue of €1.4M (-80.8% Y/Y). As of June 30, 2023 cash and cash equivalents totaled €120.1 million compared to €190.3 million on December 31, 2022. B...

AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for accelerated approval. AFM24 monotherapy: Clinical activity in 7 out of 15 heavily pretreated p...

2023-08-09 12:03:56 ET Affimed ( NASDAQ: AFMD ) is scheduled to announce Q2 earnings results on Thursday, August 10th, before market open. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $4.75M (-34.9% Y/Y). Over the last 3 months, EPS estima...

HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2023 results and corporate update on Thursday, A...

Stable disease was observed in three out of seven heavily pretreated patients No dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), ...